{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:25:26Z","timestamp":1790166326141,"version":"4.1.0"},"reference-count":232,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T00:00:00Z","timestamp":1536969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T00:00:00Z","timestamp":1536969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1111\/jcpt.12759","type":"journal-article","created":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T13:17:08Z","timestamp":1537103828000},"page":"6-22","source":"Crossref","is-referenced-by-count":50,"title":["Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead"],"prefix":"10.1155","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8280-6467","authenticated-orcid":false,"given":"Rashmi R.","family":"Shah","sequence":"first","affiliation":[{"name":"Pharmaceutical Consultant; Gerrards Cross Buckinghamshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Stonier","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Medicine; School of Cancer and Pharmaceutical Sciences; Faculty of Life Sciences and Medicine; King's College; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,15]]},"reference":[{"key":"10.1111\/jcpt.12759-BIB0001|jcpt12759-cit-0001","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/bph.14081","article-title":"Inventing new therapies without reinventing the wheel: the power of drug repurposing","volume":"175","author":"Papapetropoulos","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0002|jcpt12759-cit-0002","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","article-title":"The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs","volume":"30","author":"Niraula","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12759-BIB0003|jcpt12759-cit-0003","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","article-title":"Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12759-BIB0004|jcpt12759-cit-0004","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12759-BIB0005|jcpt12759-cit-0005","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40264-016-0450-9","article-title":"Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas","volume":"39","author":"Shah","year":"2016","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12759-BIB0006|jcpt12759-cit-0006","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2217\/fon-2016-0180","article-title":"Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2016","journal-title":"Future Oncol"},{"key":"10.1111\/jcpt.12759-BIB0007|jcpt12759-cit-0007","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.2011.35.2393","article-title":"Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs","volume":"29","author":"Amir","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12759-BIB0008|jcpt12759-cit-0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.03.011","article-title":"Efficacy, safety, tolerability and price of newly approved drugs in solid tumors","volume":"56","author":"Barnes","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1111\/jcpt.12759-BIB0009|jcpt12759-cit-0009","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1158\/2159-8290.CD-13-0790","article-title":"Teaching an old dog new tricks: drug repositioning in small cell lung cancer","volume":"3","author":"Wang","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1111\/jcpt.12759-BIB0010|jcpt12759-cit-0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2013.11.002","article-title":"Medical genetic inspirations for anticancer drug repurposing","volume":"35","author":"Wang","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1111\/jcpt.12759-BIB0011|jcpt12759-cit-0011","doi-asserted-by":"crossref","first-page":"290ra89","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1111\/jcpt.12759-BIB0012|jcpt12759-cit-0012","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","article-title":"Drug repurposing from an academic perspective","volume":"8","author":"Oprea","year":"2011","journal-title":"Drug Discov Today Ther Strateg"},{"key":"10.1111\/jcpt.12759-BIB0013|jcpt12759-cit-0013","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrd4661","article-title":"Academic drug discovery within the United Kingdom: a reassessment","volume":"14","author":"Shanks","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1111\/jcpt.12759-BIB0014|jcpt12759-cit-0014","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1089\/adt.2017.821","article-title":"When enough is enough: decision criteria for moving a known drug into clinical testing for a new indication in the absence of preclinical efficacy data","volume":"15","author":"Pulley","year":"2017","journal-title":"Assay Drug Dev Technol"},{"key":"10.1111\/jcpt.12759-BIB0015|jcpt12759-cit-0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.drudis.2018.01.018","article-title":"A bibliometric review of drug repurposing","volume":"23","author":"Baker","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1111\/jcpt.12759-BIB0016|jcpt12759-cit-0016","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3332\/ecancer.2014.485","article-title":"The Repurposing Drugs in Oncology (ReDO) project","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancer"},{"key":"10.1111\/jcpt.12759-BIB0017|jcpt12759-cit-0017","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(81)92711-2","article-title":"Phenformin-induced lactic acidosis associated with impaired debrisoquine hydroxylation","volume":"1","author":"Oates","year":"1981","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12759-BIB0018|jcpt12759-cit-0018","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/jmg.22.5.361","article-title":"The genetic control of phenformin 4-hydroxylation","volume":"22","author":"Shah","year":"1985","journal-title":"J Med Genet"},{"key":"10.1111\/jcpt.12759-BIB0019|jcpt12759-cit-0019","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab"},{"key":"10.1111\/jcpt.12759-BIB0020|jcpt12759-cit-0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-016-0485-y","article-title":"Hyperglycaemia induced by novel anticancer agents: an undesirable complication or a potential therapeutic opportunity?","volume":"40","author":"Shah","year":"2017","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12759-BIB0021|jcpt12759-cit-0021","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.seminoncol.2015.09.009","article-title":"Repurposing old drugs to chemoprevention: the case of metformin","volume":"43","author":"Heckman-Stoddard","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1111\/jcpt.12759-BIB0022|jcpt12759-cit-0022","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.3748\/wjg.v22.i27.6100","article-title":"Diabetes mellitus and metformin in hepatocellular carcinoma","volume":"22","author":"Fujita","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1111\/jcpt.12759-BIB0023|jcpt12759-cit-0023","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40880-017-0184-9","article-title":"Metformin targets multiple signaling pathways in cancer","volume":"36","author":"Lei","year":"2017","journal-title":"Chin J Cancer"},{"key":"10.1111\/jcpt.12759-BIB0024|jcpt12759-cit-0024","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/cancers9050045","article-title":"Metformin in lung cancer: review of in vitro and in vivo animal studies","volume":"9","author":"Yousef","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1111\/jcpt.12759-BIB0025|jcpt12759-cit-0025","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.2147\/DDDT.S141675","article-title":"Metformin: a review of its potential indications","volume":"11","author":"Wang","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1111\/jcpt.12759-BIB0026|jcpt12759-cit-0026","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/abbs\/gmx106","article-title":"Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells","volume":"50","author":"Saini","year":"2018","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1111\/jcpt.12759-BIB0027|jcpt12759-cit-0027","doi-asserted-by":"crossref","DOI":"10.4143\/crt.2017.466","article-title":"High-dose metformin plus temozolomide shows increased anti-tumor effects in glioblastoma in vitro and in vivo compared with monotherapy","author":"Lee","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1111\/jcpt.12759-BIB0028|jcpt12759-cit-0028","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.phrs.2016.10.006","article-title":"Metformin: an anti-diabetic drug to fight cancer","volume":"113","author":"Daugan","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1111\/jcpt.12759-BIB0029|jcpt12759-cit-0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1741-7015-9-33","article-title":"Understanding the benefit of metformin use in cancer treatment","volume":"9","author":"Dowling","year":"2011","journal-title":"BMC Med"},{"key":"10.1111\/jcpt.12759-BIB0030|jcpt12759-cit-0030","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00432-016-2178-4","article-title":"Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification","volume":"142","author":"Bhaw-Luximon","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1111\/jcpt.12759-BIB0031|jcpt12759-cit-0031","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1515\/hsz-2017-0271","article-title":"Metformin-induced anticancer activities: recent insights","volume":"399","author":"Safe","year":"2018","journal-title":"Biol Chem"},{"key":"10.1111\/jcpt.12759-BIB0032|jcpt12759-cit-0032","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40618-016-0508-7","article-title":"Insulin, insulin receptors, and cancer","volume":"39","author":"Vigneri","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/jcpt.12759-BIB0033|jcpt12759-cit-0033","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/er.2017-00073","article-title":"Insulin receptor isoforms in physiology and disease: an updated view","volume":"38","author":"Belfiore","year":"2017","journal-title":"Endocr Rev"},{"issue":"suppl 1","key":"10.1111\/jcpt.12759-BIB0034|jcpt12759-cit-0034","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.2011-S1-12","article-title":"Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer","volume":"16","author":"Baselga","year":"2011","journal-title":"Oncologist"},{"key":"10.1111\/jcpt.12759-BIB0035|jcpt12759-cit-0035","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-13-2613","article-title":"Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal","volume":"20","author":"Li","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0036|jcpt12759-cit-0036","doi-asserted-by":"crossref","first-page":"34442","DOI":"10.18632\/oncotarget.9120","article-title":"Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0037|jcpt12759-cit-0037","doi-asserted-by":"crossref","first-page":"78787","DOI":"10.18632\/oncotarget.12859","article-title":"Metformin treatment reduces temozolomide resistance of glioblastoma cells","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0038|jcpt12759-cit-0038","doi-asserted-by":"crossref","first-page":"60342","DOI":"10.18632\/oncotarget.19466","article-title":"Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathway","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0039|jcpt12759-cit-0039","doi-asserted-by":"crossref","first-page":"18226","DOI":"10.1073\/pnas.1317577110","article-title":"Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma","volume":"110","author":"Yuan","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jcpt.12759-BIB0040|jcpt12759-cit-0040","doi-asserted-by":"crossref","first-page":"100113","DOI":"10.18632\/oncotarget.22012","article-title":"Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer","volume":"8","author":"Jackson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0041|jcpt12759-cit-0041","doi-asserted-by":"crossref","first-page":"e71583","DOI":"10.1371\/journal.pone.0071583","article-title":"Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review","volume":"8","author":"Franciosi","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1111\/jcpt.12759-BIB0042|jcpt12759-cit-0042","doi-asserted-by":"crossref","first-page":"636927","DOI":"10.1155\/2013\/636927","article-title":"Risk of cancer in diabetes: the effect of metformin","volume":"2013","author":"Malek","year":"2013","journal-title":"ISRN Endocrinol"},{"key":"10.1111\/jcpt.12759-BIB0043|jcpt12759-cit-0043","doi-asserted-by":"crossref","first-page":"10147","DOI":"10.1038\/srep10147","article-title":"Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1111\/jcpt.12759-BIB0044|jcpt12759-cit-0044","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.diabet.2017.03.004","article-title":"Metformin is associated with a lower risk of colorectal cancer in Taiwanese patients with type 2 diabetes: a retrospective cohort analysis","volume":"43","author":"Tseng","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1111\/jcpt.12759-BIB0045|jcpt12759-cit-0045","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00432-010-0960-2","article-title":"Diabetes and prognosis in a breast cancer cohort","volume":"137","author":"Schrauder","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1111\/jcpt.12759-BIB0046|jcpt12759-cit-0046","doi-asserted-by":"crossref","first-page":"e3528","DOI":"10.1097\/MD.0000000000003528","article-title":"The effect of diabetes mellitus on lung cancer prognosis: a PRISMA-compliant meta-analysis of cohort studies","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/jcpt.12759-BIB0047|jcpt12759-cit-0047","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1186\/s40064-016-3233-y","article-title":"Diabetes and mortality in patients with prostate cancer: a meta-analysis","volume":"5","author":"Lee","year":"2016","journal-title":"Springerplus"},{"key":"10.1111\/jcpt.12759-BIB0048|jcpt12759-cit-0048","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clon.2018.01.003","article-title":"Hyperglycaemia and survival in solid tumours: a systematic review and meta-analysis","volume":"30","author":"Barua","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1111\/jcpt.12759-BIB0049|jcpt12759-cit-0049","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ijc.30480","article-title":"Prospective study of type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer","volume":"140","author":"H\u00e4ggstr\u00f6m","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1111\/jcpt.12759-BIB0050|jcpt12759-cit-0050","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1634\/theoncologist.2013-0111","article-title":"Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis","volume":"18","author":"Yin","year":"2013","journal-title":"Oncologist"},{"key":"10.1111\/jcpt.12759-BIB0051|jcpt12759-cit-0051","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.amjms.2017.05.006","article-title":"Metformin has positive therapeutic effects in colon cancer and lung cancer","volume":"354","author":"Henderson","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1111\/jcpt.12759-BIB0052|jcpt12759-cit-0052","doi-asserted-by":"crossref","first-page":"e0191129","DOI":"10.1371\/journal.pone.0191129","article-title":"Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: a population-based retrospective cohort study","volume":"13","author":"Chuang","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1111\/jcpt.12759-BIB0053|jcpt12759-cit-0053","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1158\/0008-5472.CAN-17-0687","article-title":"Diabetes treatments and risks of adverse breast cancer outcomes among early-stage breast cancer patients: a SEER-Medicare analysis","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0054|jcpt12759-cit-0054","doi-asserted-by":"crossref","first-page":"66202","DOI":"10.18632\/oncotarget.11033","article-title":"Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0055|jcpt12759-cit-0055","doi-asserted-by":"crossref","first-page":"e6888","DOI":"10.1097\/MD.0000000000006888","article-title":"Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients","volume":"96","author":"Ma","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/jcpt.12759-BIB0056|jcpt12759-cit-0056","doi-asserted-by":"crossref","first-page":"100449","DOI":"10.18632\/oncotarget.22117","article-title":"The impact of metformin use on survival in prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Xiao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0057|jcpt12759-cit-0057","doi-asserted-by":"crossref","first-page":"e2749","DOI":"10.1097\/MD.0000000000002749","article-title":"Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus: a meta-analysis","volume":"95","author":"He","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/jcpt.12759-BIB0058|jcpt12759-cit-0058","doi-asserted-by":"crossref","first-page":"5063239","DOI":"10.1155\/2017\/5063239","article-title":"Metformin improves overall survival of colorectal cancer patients with diabetes: a meta-analysis","volume":"2017","author":"Meng","year":"2017","journal-title":"J Diabetes Res"},{"key":"10.1111\/jcpt.12759-BIB0059|jcpt12759-cit-0059","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.maturitas.2017.04.001","article-title":"Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus","volume":"101","author":"Perez-Lopez","year":"2017","journal-title":"Maturitas"},{"key":"10.1111\/jcpt.12759-BIB0060|jcpt12759-cit-0060","doi-asserted-by":"crossref","first-page":"5905384","DOI":"10.1155\/2017\/5905384","article-title":"Metformin use is associated with reduced incidence and improved survival of endometrial cancer: a meta-analysis","volume":"2017","author":"Tang","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1111\/jcpt.12759-BIB0061|jcpt12759-cit-0061","first-page":"483","article-title":"Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes: a meta-analysis","volume":"8","author":"Xin","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"10.1111\/jcpt.12759-BIB0062|jcpt12759-cit-0062","doi-asserted-by":"crossref","first-page":"e6229","DOI":"10.1097\/MD.0000000000006229","article-title":"No association between metformin use and survival in patients with pancreatic cancer: an observational cohort study","volume":"96","author":"Frouws","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/jcpt.12759-BIB0063|jcpt12759-cit-0063","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.clgc.2016.07.003","article-title":"Comment on: Bono P, Oudard S, Bodrogi I, et al. Outcomes in patients with metastatic renal cell carcinoma who develop everolimus-related hyperglycemia and hypercholesterolemia: combined subgroup analyses of the RECORD-1 and REACT trials (Clin Genitourin Cancer 2016)","volume":"15","author":"Shah","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1111\/jcpt.12759-BIB0064|jcpt12759-cit-0064","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cam4.259","article-title":"The effect of metformin on breast cancer outcomes in patients with type 2 diabetes","volume":"3","author":"Oppong","year":"2014","journal-title":"Cancer Med"},{"key":"10.1111\/jcpt.12759-BIB0065|jcpt12759-cit-0065","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.juro.2016.10.069","article-title":"The effect of metformin use during docetaxel chemotherapy on prostate cancer specific and overall survival of diabetic patients with castration resistant prostate cancer","volume":"197","author":"Mayer","year":"2017","journal-title":"J Urol"},{"key":"10.1111\/jcpt.12759-BIB0066|jcpt12759-cit-0066","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00432-016-2148-x","article-title":"Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer","volume":"142","author":"Oh","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1111\/jcpt.12759-BIB0067|jcpt12759-cit-0067","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.7314\/APJCP.2015.16.15.6621","article-title":"Metformin addition to chemotherapy in stage IV non-small cell lung cancer: an open label randomized controlled study","volume":"16","author":"Sayed","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1111\/jcpt.12759-BIB0068|jcpt12759-cit-0068","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1470-2045(15)00027-3","article-title":"Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial","volume":"16","author":"Kordes","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1111\/jcpt.12759-BIB0069|jcpt12759-cit-0069","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/1078-0432.CCR-15-1722","article-title":"(Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase II trial","volume":"22","author":"Reni","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0070|jcpt12759-cit-0070","doi-asserted-by":"crossref","first-page":"84224","DOI":"10.18632\/oncotarget.20478","article-title":"A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0071|jcpt12759-cit-0071","doi-asserted-by":"crossref","first-page":"ed76","DOI":"10.3332\/ecancer.2018.ed76","article-title":"Does the oncology community have a rejection bias when it comes to repurposed drugs?","volume":"12","author":"Gyawali","year":"2018","journal-title":"Ecancer"},{"key":"10.1111\/jcpt.12759-BIB0072|jcpt12759-cit-0072","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10637-017-0478-4","article-title":"A phase Ib study of everolimus combined with metformin for patients with advanced cancer","volume":"36","author":"Molenaar","year":"2018","journal-title":"Invest New Drugs"},{"key":"10.1111\/jcpt.12759-BIB0073|jcpt12759-cit-0073","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cllc.2014.06.010","article-title":"A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial","volume":"16","author":"Fasano","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1111\/jcpt.12759-BIB0074|jcpt12759-cit-0074","doi-asserted-by":"crossref","first-page":"e000132","DOI":"10.1136\/esmoopen-2016-000132","article-title":"Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer","volume":"2","author":"Morgillo","year":"2017","journal-title":"ESMO Open"},{"key":"10.1111\/jcpt.12759-BIB0075|jcpt12759-cit-0075","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2337\/dc09-1380","article-title":"Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16","volume":"33","author":"Landman","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12759-BIB0076|jcpt12759-cit-0076","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s11605-016-3173-4","article-title":"Metformin use is associated with improved survival in patients undergoing resection for pancreatic cancer","volume":"20","author":"Cerullo","year":"2016","journal-title":"J Gastrointest Surg"},{"key":"10.1111\/jcpt.12759-BIB0077|jcpt12759-cit-0077","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4111\/icu.2016.57.3.157","article-title":"Potential role for metformin in urologic oncology","volume":"57","author":"Sayyid","year":"2016","journal-title":"Investig Clin Urol"},{"key":"10.1111\/jcpt.12759-BIB0078|jcpt12759-cit-0078","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/ijc.29944","article-title":"Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: results from the women's health initiative","volume":"138","author":"Gong","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1111\/jcpt.12759-BIB0079|jcpt12759-cit-0079","first-page":"435","article-title":"Pharmacodynamic properties of N-dipropylacetic acid","volume":"18","author":"Meunier","year":"1963","journal-title":"Therapie"},{"key":"10.1111\/jcpt.12759-BIB0080|jcpt12759-cit-0080","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(82)90908-4","article-title":"Maternal valproic acid and congenital neural tube defects","volume":"2","author":"Robert","year":"1982","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12759-BIB0081|jcpt12759-cit-0081","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7","article-title":"Histone deacetylases, transcriptional control, and cancer","volume":"184","author":"Cress","year":"2000","journal-title":"J Cell Physiol"},{"key":"10.1111\/jcpt.12759-BIB0082|jcpt12759-cit-0082","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF03402044","article-title":"Histone acetylation modifiers in the pathogenesis of malignant disease","volume":"6","author":"Mahlknecht","year":"2000","journal-title":"Mol Med"},{"key":"10.1111\/jcpt.12759-BIB0083|jcpt12759-cit-0083","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/PL00000896","article-title":"Histone acetylation and disease","volume":"58","author":"Timmermann","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"10.1111\/jcpt.12759-BIB0084|jcpt12759-cit-0084","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1111\/jcpt.12759-BIB0085|jcpt12759-cit-0085","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1043-2760(01)00438-6","article-title":"Histone deacetylase as a therapeutic target","volume":"12","author":"Kr\u00e4mer","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"10.1111\/jcpt.12759-BIB0086|jcpt12759-cit-0086","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1574892810666150317144511","article-title":"HDAC inhibitors as novel anti-cancer therapeutics","volume":"10","author":"Souza","year":"2015","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1111\/jcpt.12759-BIB0087|jcpt12759-cit-0087","doi-asserted-by":"crossref","first-page":"e1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1111\/jcpt.12759-BIB0088|jcpt12759-cit-0088","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/pgs-2016-0113","article-title":"Pharmacogenomics and histone deacetylase inhibitors","volume":"17","author":"Goey","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jcpt.12759-BIB0089|jcpt12759-cit-0089","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1111\/jcpt.12759-BIB0090|jcpt12759-cit-0090","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/med.10017","article-title":"Anti-tumor mechanisms of valproate: a novel role for an old drug","volume":"22","author":"Blaheta","year":"2002","journal-title":"Med Res Rev"},{"key":"10.1111\/jcpt.12759-BIB0091|jcpt12759-cit-0091","doi-asserted-by":"crossref","first-page":"18851","DOI":"10.1074\/jbc.M312795200","article-title":"Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis","volume":"279","author":"Lagace","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1111\/jcpt.12759-BIB0092|jcpt12759-cit-0092","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"Chateauvieux","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1111\/jcpt.12759-BIB0093|jcpt12759-cit-0093","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC","volume":"15","author":"Munster","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0094|jcpt12759-cit-0094","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1868-7083-5-12","article-title":"Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents","volume":"5","author":"Fredly","year":"2013","journal-title":"Clin Epigenetics"},{"key":"10.1111\/jcpt.12759-BIB0095|jcpt12759-cit-0095","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3892\/ol.2016.4880","article-title":"Valproic acid induces autophagy by suppressing the Akt\/mTOR pathway in human prostate cancer cells","volume":"12","author":"Xia","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1111\/jcpt.12759-BIB0096|jcpt12759-cit-0096","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s12094-016-1494-0","article-title":"Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1\u03b1\/VEGF signals","volume":"18","author":"Zhao","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"10.1111\/jcpt.12759-BIB0097|jcpt12759-cit-0097","doi-asserted-by":"crossref","first-page":"14666","DOI":"10.18632\/oncotarget.14716","article-title":"Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression","volume":"8","author":"Tseng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0098|jcpt12759-cit-0098","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13402-017-0314-z","article-title":"Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells","volume":"40","author":"Gilardini Montani","year":"2017","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1111\/jcpt.12759-BIB0099|jcpt12759-cit-0099","first-page":"3138","article-title":"Valproic acid, targets papillary thyroid cancer through inhibition of c-Met signalling pathway","volume":"9","author":"Fu","year":"2017","journal-title":"Am J Transl Res"},{"key":"10.1111\/jcpt.12759-BIB0100|jcpt12759-cit-0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3325\/cmj.2017.58.349","article-title":"The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells","volume":"58","author":"Ma","year":"2017","journal-title":"Croat Med J"},{"key":"10.1111\/jcpt.12759-BIB0101|jcpt12759-cit-0101","doi-asserted-by":"crossref","first-page":"110016","DOI":"10.18632\/oncotarget.22454","article-title":"HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells","volume":"8","author":"Juengel","year":"2017","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0102|jcpt12759-cit-0102","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1021\/tx0502241","article-title":"Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives","volume":"19","author":"Eikel","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1111\/jcpt.12759-BIB0103|jcpt12759-cit-0103","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/cncr.28479","article-title":"Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer","volume":"120","author":"Kang","year":"2014","journal-title":"Cancer"},{"key":"10.1111\/jcpt.12759-BIB0104|jcpt12759-cit-0104","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/cen.13154","article-title":"A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin","volume":"86","author":"Nilubol","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/jcpt.12759-BIB0105|jcpt12759-cit-0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1055\/s-2008-1043809","article-title":"Valproic acid for the treatment of pediatric malignant glioma","volume":"211","author":"Driever","year":"1999","journal-title":"Klin Padiatr"},{"key":"10.1111\/jcpt.12759-BIB0106|jcpt12759-cit-0106","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2217\/cns-2016-0004","article-title":"Does valproic acid affect tumor growth and improve survival in glioblastomas?","volume":"5","author":"Rud\u00e0","year":"2016","journal-title":"CNS Oncol"},{"key":"10.1111\/jcpt.12759-BIB0107|jcpt12759-cit-0107","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.seizure.2014.06.015","article-title":"Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review","volume":"23","author":"Yuan","year":"2014","journal-title":"Seizure"},{"key":"10.1111\/jcpt.12759-BIB0108|jcpt12759-cit-0108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7314\/APJCP.2016.17.2.463","article-title":"Roles of valproic acid in improving radiation therapy for glioblastoma: a review of literature focusing on clinical evidence","volume":"17","author":"Ochiai","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1111\/jcpt.12759-BIB0109|jcpt12759-cit-0109","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11060-016-2191-0","article-title":"Does the choice of antiepileptic drug affect survival in glioblastoma patients?","volume":"129","author":"Knudsen-Baas","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1111\/jcpt.12759-BIB0110|jcpt12759-cit-0110","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/neuonc\/nov238","article-title":"Prognostic relevance of epilepsy at presentation in glioblastoma patients","volume":"18","author":"Berendsen","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1111\/jcpt.12759-BIB0111|jcpt12759-cit-0111","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.clineuro.2015.10.002","article-title":"Prognostic implications of epilepsy in glioblastomas","volume":"139","author":"Toledo","year":"2015","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1111\/jcpt.12759-BIB0112|jcpt12759-cit-0112","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11060-016-2054-8","article-title":"Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II\/III gliomas treated with temozolomide","volume":"127","author":"Redjal","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1111\/jcpt.12759-BIB0113|jcpt12759-cit-0113","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1586\/14737140.2014.940329","article-title":"Could valproic acid be an effective anticancer agent? The evidence so far","volume":"14","author":"Brodie","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1111\/jcpt.12759-BIB0114|jcpt12759-cit-0114","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/IGC.0000000000000814","article-title":"Valproic acid as a promising co-treatment with paclitaxel and doxorubicin in different ovarian carcinoma cell lines","volume":"26","author":"Kwieci\u0144ska","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"10.1111\/jcpt.12759-BIB0115|jcpt12759-cit-0115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1515\/hsz-2016-0307","article-title":"Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1","volume":"398","author":"Chen","year":"2017","journal-title":"Biol Chem"},{"key":"10.1111\/jcpt.12759-BIB0116|jcpt12759-cit-0116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2017.08.002","article-title":"Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway","volume":"58","author":"Tian","year":"2017","journal-title":"DNA Repair (Amst)"},{"key":"10.1111\/jcpt.12759-BIB0117|jcpt12759-cit-0117","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.18632\/oncotarget.6802","article-title":"Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression","volume":"7","author":"Terranova-Barberio","year":"2016","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0118|jcpt12759-cit-0118","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/ijms19010164","article-title":"The histone deacetylase inhibitor valproic acid exerts a synergistic cytotoxicity with the DNA-damaging drug ellipticine in neuroblastoma cells","volume":"19","author":"Cerna","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1111\/jcpt.12759-BIB0119|jcpt12759-cit-0119","doi-asserted-by":"crossref","first-page":"83155","DOI":"10.18632\/oncotarget.17950","article-title":"HDAC inhibitors enhance the immunotherapy response of melanoma cells","volume":"8","author":"Booth","year":"2017","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0120|jcpt12759-cit-0120","first-page":"2503","article-title":"Combination of sorafenib and valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt","volume":"7","author":"Zhu","year":"2017","journal-title":"Am J Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0121|jcpt12759-cit-0121","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/15384047.2017.1394556","article-title":"The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1\/ATG5 -dependent fashion by the irreversible ERBB1\/2\/4 inhibitor neratinib","volume":"19","author":"Booth","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1111\/jcpt.12759-BIB0122|jcpt12759-cit-0122","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3892\/ijmm.2016.2552","article-title":"Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis","volume":"37","author":"Liu","year":"2016","journal-title":"Int J Mol Med"},{"key":"10.1111\/jcpt.12759-BIB0123|jcpt12759-cit-0123","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-17-0074","article-title":"The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer","volume":"16","author":"Tran","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/jcpt.12759-BIB0124|jcpt12759-cit-0124","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.bjc.6604817","article-title":"A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma","volume":"100","author":"Rocca","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1111\/jcpt.12759-BIB0125|jcpt12759-cit-0125","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1248\/bpb.b16-01025","article-title":"Histone deacetylase inhibitors sensitize murine B16F10 melanoma cells to carbon ion irradiation by inducing G1 phase arrest","volume":"40","author":"Saito","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"10.1111\/jcpt.12759-BIB0126|jcpt12759-cit-0126","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3892\/ol.2017.5792","article-title":"CHK2 is involved in the p53-independent radiosensitizing effects of valproic acid","volume":"13","author":"Choo","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1111\/jcpt.12759-BIB0127|jcpt12759-cit-0127","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/ijms18051027","article-title":"The effect of VPA on increasing radiosensitivity in osteosarcoma cells and primary-culture cells from chemical carcinogen-induced breast cancer in rats","volume":"18","author":"Liu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1111\/jcpt.12759-BIB0128|jcpt12759-cit-0128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13046-017-0647-5","article-title":"Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53","volume":"36","author":"Terranova-Barberio","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0129|jcpt12759-cit-0129","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/13543784.2012.694425","article-title":"Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results","volume":"21","author":"Berendsen","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/jcpt.12759-BIB0130|jcpt12759-cit-0130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4143\/crt.2014.026","article-title":"In vitro and in vivo radiosensitizing effect of valproic acid on fractionated irradiation","volume":"47","author":"Chie","year":"2015","journal-title":"Cancer Res Treat"},{"key":"10.1111\/jcpt.12759-BIB0131|jcpt12759-cit-0131","doi-asserted-by":"crossref","first-page":"35004","DOI":"10.18632\/oncotarget.5253","article-title":"Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells","volume":"6","author":"Thotala","year":"2015","journal-title":"Oncotarget"},{"key":"10.1111\/jcpt.12759-BIB0132|jcpt12759-cit-0132","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/jcpt.12759-BIB0133|jcpt12759-cit-0133","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-016-2167-1","article-title":"Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma","volume":"73","author":"Watanabe","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0134|jcpt12759-cit-0134","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1186\/s12885-016-2957-y","article-title":"Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and\/or metastatic squamous cell carcinoma of head and neck-V-CHANCE trial","volume":"16","author":"Caponigro","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1111\/jcpt.12759-BIB0135|jcpt12759-cit-0135","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12885-015-1432-5","article-title":"DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy","volume":"15","author":"Grishina","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1111\/jcpt.12759-BIB0136|jcpt12759-cit-0136","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/jcb.26512","article-title":"Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors","volume":"119","author":"Tarasenko","year":"2018","journal-title":"J Cell Biochem"},{"key":"10.1111\/jcpt.12759-BIB0137|jcpt12759-cit-0137","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1124\/mol.109.058651","article-title":"Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor","volume":"76","author":"Deml","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0138|jcpt12759-cit-0138","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00210-013-0926-4","article-title":"Pharmacological profile of astemizole-derived compounds at the histamine H1 and H4 receptor - H1\/H4 receptor selectivity","volume":"387","author":"Wagner","year":"2014","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0139|jcpt12759-cit-0139","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1540-8167.1999.tb00264.x","article-title":"Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole","volume":"10","author":"Zhou","year":"1999","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1111\/jcpt.12759-BIB0140|jcpt12759-cit-0140","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/S0735-1097(96)00352-X","article-title":"Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole","volume":"28","author":"Vorperian","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12759-BIB0141|jcpt12759-cit-0141","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40264-013-0016-z","article-title":"Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated?","volume":"36","author":"Stockbridge","year":"2013","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12759-BIB0142|jcpt12759-cit-0142","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1468-1331.2010.03187.x","article-title":"Allergy and risk of glioma: a meta-analysis","volume":"18","author":"Chen","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1111\/jcpt.12759-BIB0143|jcpt12759-cit-0143","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/jnci\/djr361","article-title":"Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies","volume":"103","author":"Calboli","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/jcpt.12759-BIB0144|jcpt12759-cit-0144","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1007\/s13277-013-1514-4","article-title":"Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects","volume":"35","author":"Zhao","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1111\/jcpt.12759-BIB0145|jcpt12759-cit-0145","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1158\/0008-5472.CAN-04-3728","article-title":"Polymorphisms associated with asthma are inversely related to glioblastoma multiforme","volume":"65","author":"Schwartzbaum","year":"2005","journal-title":"Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0146|jcpt12759-cit-0146","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/1055-9965.EPI-15-0847","article-title":"Approaching a scientific consensus on the association between allergies and glioma risk: a report from the Glioma International Case-Control Study","volume":"25","author":"Amirian","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1111\/jcpt.12759-BIB0147|jcpt12759-cit-0147","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1158\/0008-5472.CAN-04-1706","article-title":"Reduced immunoglobulin E and allergy among adults with glioma compared with controls","volume":"64","author":"Wiemels","year":"2004","journal-title":"Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0148|jcpt12759-cit-0148","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/ijc.24369","article-title":"IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era","volume":"125","author":"Wiemels","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1111\/jcpt.12759-BIB0149|jcpt12759-cit-0149","doi-asserted-by":"crossref","first-page":"e0137503","DOI":"10.1371\/journal.pone.0137503","article-title":"Association between prediagnostic allergy-related serum cytokines and glioma","volume":"10","author":"Schwartzbaum","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1111\/jcpt.12759-BIB0150|jcpt12759-cit-0150","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ijc.25883","article-title":"Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies","volume":"129","author":"Scheurer","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1111\/jcpt.12759-BIB0151|jcpt12759-cit-0151","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/jnci\/86.10.770","article-title":"Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates","volume":"86","author":"Brandes","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/jcpt.12759-BIB0152|jcpt12759-cit-0152","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/jnci\/86.10.740","article-title":"Between science and technology: the case of antihistamines and cancer","volume":"86","author":"Weed","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/jcpt.12759-BIB0153|jcpt12759-cit-0153","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/jnci\/86.15.1172","article-title":"Re: enhanced cancer growth with H1-antihistamines","volume":"86","author":"Miller","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/jcpt.12759-BIB0154|jcpt12759-cit-0154","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/jnci\/86.17.1355-a","article-title":"Re: enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates","volume":"86","author":"Morris","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/jcpt.12759-BIB0155|jcpt12759-cit-0155","first-page":"797","article-title":"More questions than answers: antihistamines\u2019 link to cancer","volume":"151","author":"Robinson","year":"1994","journal-title":"CMAJ"},{"key":"10.1111\/jcpt.12759-BIB0156|jcpt12759-cit-0156","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/jnci\/87.21.1638","article-title":"Re: enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates","volume":"87","author":"Kurokawa","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/jcpt.12759-BIB0157|jcpt12759-cit-0157","first-page":"5589","article-title":"Carcinogenicity studies of astemizole in mice and rats","volume":"55","author":"Benze","year":"1995","journal-title":"Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0158|jcpt12759-cit-0158","first-page":"3796","article-title":"Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses","volume":"52","author":"Brandes","year":"1992","journal-title":"Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0159|jcpt12759-cit-0159","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00232-005-0776-1","article-title":"Role of voltage-gated potassium channels in cancer","volume":"205","author":"Pardo","year":"2005","journal-title":"J Membr Biol"},{"key":"10.1111\/jcpt.12759-BIB0160|jcpt12759-cit-0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1477-7819-8-113","article-title":"Eag and HERG potassium channels as novel therapeutic targets in cancer","volume":"8","author":"Asher","year":"2010","journal-title":"World J Surg Oncol"},{"key":"10.1111\/jcpt.12759-BIB0161|jcpt12759-cit-0161","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrc3635","article-title":"The roles of K+ channels in cancer","volume":"14","author":"Pardo","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/jcpt.12759-BIB0162|jcpt12759-cit-0162","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/mol.113.091439","article-title":"Long-term channel block is required to inhibit cellular transformation by human ether-\u00e0-go-go-related gene (hERG1) potassium channels","volume":"86","author":"Pier","year":"2014","journal-title":"Mol Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0163|jcpt12759-cit-0163","first-page":"2160","article-title":"Expression of human ether-a-go-go-related gene in laryngeal carcinoma","volume":"29","author":"Liang","year":"2015","journal-title":"Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"10.1111\/jcpt.12759-BIB0164|jcpt12759-cit-0164","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.vascn.2013.03.005","article-title":"A history of the role of the hERG channel in cardiac risk assessment","volume":"68","author":"Rampe","year":"2013","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1111\/jcpt.12759-BIB0165|jcpt12759-cit-0165","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1074\/jbc.M210789200","article-title":"Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells","volume":"278","author":"Crociani","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/jcpt.12759-BIB0166|jcpt12759-cit-0166","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/ph3041202","article-title":"New trends in cancer therapy: targeting ion channels and transporters","volume":"3","author":"Arcangeli","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1111\/jcpt.12759-BIB0167|jcpt12759-cit-0167","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1038\/cddis.2011.77","article-title":"Novel roles for hERG K+ channels in cell proliferation and apoptosis","volume":"2","author":"Jehle","year":"2011","journal-title":"Cell Death Dis"},{"key":"10.1111\/jcpt.12759-BIB0168|jcpt12759-cit-0168","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drup.2015.06.002","article-title":"Novel perspectives in cancer therapy: targeting ion channels","volume":"21-22","author":"Arcangeli","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1111\/jcpt.12759-BIB0169|jcpt12759-cit-0169","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/cancers7020813","article-title":"Voltage-gated ion channels in cancer cell proliferation","volume":"7","author":"Rao","year":"2015","journal-title":"Cancers (Basel)"},{"key":"10.1111\/jcpt.12759-BIB0170|jcpt12759-cit-0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1078-0432.CCR-16-2322","article-title":"hERG Channels: from antitargets to novel targets for cancer therapy","volume":"23","author":"Arcangeli","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0171|jcpt12759-cit-0171","first-page":"1511","article-title":"Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7","volume":"19","author":"Roy","year":"2008","journal-title":"Oncol Rep"},{"key":"10.1111\/jcpt.12759-BIB0172|jcpt12759-cit-0172","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1073\/pnas.91.8.3438","article-title":"A family of potassium channel genes related to eag in Drosophila and mammals","volume":"91","author":"Warmke","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jcpt.12759-BIB0173|jcpt12759-cit-0173","first-page":"815","article-title":"Herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells?","volume":"58","author":"Bianchi","year":"1998","journal-title":"Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0174|jcpt12759-cit-0174","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1054\/bjoc.2000.1497","article-title":"HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium","volume":"83","author":"Cherubini","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1111\/jcpt.12759-BIB0175|jcpt12759-cit-0175","first-page":"4843","article-title":"HERG K+ channel, a regulator of tumor cell apoptosis and proliferation","volume":"62","author":"Wang","year":"2002","journal-title":"Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0176|jcpt12759-cit-0176","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1038\/sj.leu.2402572","article-title":"HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors","volume":"16","author":"Pillozzi","year":"2002","journal-title":"Leukemia"},{"key":"10.1111\/jcpt.12759-BIB0177|jcpt12759-cit-0177","doi-asserted-by":"crossref","first-page":"18528","DOI":"10.1074\/jbc.M200592200","article-title":"Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells","volume":"277","author":"Smith","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1111\/jcpt.12759-BIB0178|jcpt12759-cit-0178","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/08880018.2014.949941","article-title":"herg1b expression as a potential specific marker in pediatric acute myeloid leukemia patients with HERG 897K\/K genotype","volume":"32","author":"Erdem","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1111\/jcpt.12759-BIB0179|jcpt12759-cit-0179","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1746-1596-5-78","article-title":"The Eag potassium channel as a new prognostic marker in ovarian cancer","volume":"5","author":"Asher","year":"2010","journal-title":"Diagn Pathol"},{"key":"10.1111\/jcpt.12759-BIB0180|jcpt12759-cit-0180","first-page":"433","article-title":"Human ether-\u00e0-go-go-related gene expression is essential for cisplatin to induce apoptosis in human gastric cancer","volume":"27","author":"Zhang","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1111\/jcpt.12759-BIB0181|jcpt12759-cit-0181","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.3892\/ol.2016.4992","article-title":"Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomide","volume":"12","author":"Sales","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1111\/jcpt.12759-BIB0182|jcpt12759-cit-0182","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4161\/cbt.4.3.1500","article-title":"The potent inhibitory effects of cisapride, a specific blocker for human ether-a-go-go-related gene (HERG) channel, on gastric cancer cells","volume":"4","author":"Shao","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1111\/jcpt.12759-BIB0183|jcpt12759-cit-0183","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/cbt.7.1.5126","article-title":"Expression and significance of HERG protein in gastric cancer","volume":"7","author":"Shao","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1111\/jcpt.12759-BIB0184|jcpt12759-cit-0184","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1158\/1078-0432.CCR-15-3169","article-title":"Administration of non-torsadogenic human ether-\u00e0-go-go-related gene inhibitors is associated with better survival for high hERG-expressing glioblastoma patients","volume":"23","author":"Pointer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1111\/jcpt.12759-BIB0185|jcpt12759-cit-0185","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/mol.59.1.122","article-title":"Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG","volume":"59","author":"Kang","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0186|jcpt12759-cit-0186","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0022-3565(24)38820-2","article-title":"Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics","volume":"296","author":"Anderson","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/jcpt.12759-BIB0187|jcpt12759-cit-0187","first-page":"835","article-title":"Torsade de pointes probably induced by sparfloxacin","volume":"51","author":"Ahluwalia","year":"2003","journal-title":"J Assoc Physicians India"},{"key":"10.1111\/jcpt.12759-BIB0188|jcpt12759-cit-0188","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2007.07.070","article-title":"In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation","volume":"577","author":"Lu","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0189|jcpt12759-cit-0189","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/BF03261967","article-title":"Early investigation of QTc liability: the role of multiple ascending dose (MAD) study","volume":"35","author":"Shah","year":"2012","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12759-BIB0190|jcpt12759-cit-0190","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1111\/bph.13870","article-title":"The anaesthetized rabbit with acute atrioventricular block provides a new model for detecting drug-induced torsade de pointes","volume":"174","author":"Hagiwara","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0191|jcpt12759-cit-0191","first-page":"1747","article-title":"HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells","volume":"23","author":"Gong","year":"2010","journal-title":"Oncol Rep"},{"key":"10.1111\/jcpt.12759-BIB0192|jcpt12759-cit-0192","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk\/benefit","volume":"38","author":"Shah","year":"2015","journal-title":"Drug Saf"},{"key":"10.1111\/jcpt.12759-BIB0193|jcpt12759-cit-0193","doi-asserted-by":"crossref","first-page":"131ra50","DOI":"10.1126\/scitranslmed.3003623","article-title":"Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome","volume":"4","author":"Lu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1111\/jcpt.12759-BIB0194|jcpt12759-cit-0194","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.tcm.2017.05.005","article-title":"Acquired long QT syndrome and phosphoinositide 3-kinase","volume":"27","author":"Cohen","year":"2017","journal-title":"Trends Cardiovasc Med"},{"key":"10.1111\/jcpt.12759-BIB0195|jcpt12759-cit-0195","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jcp.21065","article-title":"IGF-1 activates hEAG K+ channels through an Akt-dependent signaling pathway in breast cancer cells: role in cell proliferation","volume":"212","author":"Borowiec","year":"2007","journal-title":"J Cell Physiol"},{"key":"10.1111\/jcpt.12759-BIB0196|jcpt12759-cit-0196","doi-asserted-by":"crossref","first-page":"H1446","DOI":"10.1152\/ajpheart.01356.2005","article-title":"Restoring depressed HERG K+ channel function as a mechanism for insulin treatment of abnormal QT prolongation and associated arrhythmias in diabetic rabbits","volume":"291","author":"Zhang","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1111\/jcpt.12759-BIB0197|jcpt12759-cit-0197","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/toxsci\/kfw104","article-title":"Histone deacetylase inhibitors prolong cardiac repolarization through transcriptional mechanisms","volume":"153","author":"Spence","year":"2016","journal-title":"Toxicol Sci"},{"key":"10.1111\/jcpt.12759-BIB0198|jcpt12759-cit-0198","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/15563650.2013.775580","article-title":"QTc prolongation and valproate toxicity","volume":"51","author":"Kazim","year":"2013","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1111\/jcpt.12759-BIB0199|jcpt12759-cit-0199","doi-asserted-by":"crossref","first-page":"656","DOI":"10.4103\/1735-1995.166211","article-title":"Favorable results after conservative management of 316 valproate intoxicated patients","volume":"20","author":"Shadnia","year":"2015","journal-title":"J Res Med Sci"},{"key":"10.1111\/jcpt.12759-BIB0200|jcpt12759-cit-0200","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/0269881116684337","article-title":"Psychotropic drugs and ventricular repolarisation: the effects on QT interval, T-peak to T-end interval and QT dispersion","volume":"31","author":"Acciavatti","year":"2017","journal-title":"J Psychopharmacol"},{"key":"10.1111\/jcpt.12759-BIB0201|jcpt12759-cit-0201","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/187152011795347513","article-title":"Astemizole: an old anti-histamine as a new promising anti-cancer drug","volume":"11","author":"Garc\u00eda-Quiroz","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1111\/jcpt.12759-BIB0202|jcpt12759-cit-0202","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/IGC.0000000000000151","article-title":"Antiproliferative and proapoptotic effects of astemizole on cervical cancer cells","volume":"24","author":"Guadalupe Chavez-L\u00f3pez","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1111\/jcpt.12759-BIB0203|jcpt12759-cit-0203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.14715\/cmb\/2017.63.12.4","article-title":"Astemizole inhibits cell proliferation in human prostate tumorigenic cells expressing ether \u00e0-go-go-1 potassium channels","volume":"63","author":"Bernal-Ramos","year":"2017","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"10.1111\/jcpt.12759-BIB0204|jcpt12759-cit-0204","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.2147\/OTT.S144506","article-title":"The combination astemizole-gefitinib as a potential therapy for human lung cancer","volume":"10","author":"Ch\u00e1vez-L\u00f3pez","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1111\/jcpt.12759-BIB0205|jcpt12759-cit-0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clon.2015.10.004","article-title":"Repurposing vitamin D as an anticancer drug","volume":"28","author":"Gilbert","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1111\/jcpt.12759-BIB0206|jcpt12759-cit-0206","doi-asserted-by":"crossref","first-page":"e45063","DOI":"10.1371\/journal.pone.0045063","article-title":"Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy","volume":"7","author":"Garc\u00eda-Quiroz","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1111\/jcpt.12759-BIB0207|jcpt12759-cit-0207","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1186\/1471-2407-14-745","article-title":"In vivo dual targeting of the oncogenic ether-\u00e0-go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors","volume":"14","author":"Garc\u00eda-Quiroz","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1111\/jcpt.12759-BIB0208|jcpt12759-cit-0208","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.yexcr.2009.11.008","article-title":"Calcitriol inhibits ether-\u00e0 go-go potassium channel expression and cell proliferation in human breast cancer cells","volume":"316","author":"Garc\u00eda-Becerra","year":"2010","journal-title":"Exp Cell Res"},{"key":"10.1111\/jcpt.12759-BIB0209|jcpt12759-cit-0209","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jphs.2016.04.024","article-title":"Possibility as an anti-cancer drug of astemizole: evaluation of arrhythmogenicity by the chronic atrioventricular block canine model","volume":"131","author":"Izumi-Nakaseko","year":"2016","journal-title":"J Pharmacol Sci"},{"key":"10.1111\/jcpt.12759-BIB0210|jcpt12759-cit-0210","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ebiom.2016.06.013","article-title":"Repurposing cationic amphiphilic antihistamines for cancer treatment","volume":"9","author":"Ellegaard","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1111\/jcpt.12759-BIB0211|jcpt12759-cit-0211","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0014-5793(96)00355-9","article-title":"Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole","volume":"385","author":"Suessbrich","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1111\/jcpt.12759-BIB0212|jcpt12759-cit-0212","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0022-3565(24)36589-9","article-title":"Suppression of mammalian K+ channel family by ebastine","volume":"281","author":"Ko","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/jcpt.12759-BIB0213|jcpt12759-cit-0213","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1211\/0022357991773393","article-title":"Inhibitory effects of the antihistamines epinastine, terfenadine, and ebastine on potassium currents in rat ventricular myocytes","volume":"51","author":"Ohtani","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0214|jcpt12759-cit-0214","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1124\/jpet.105.093393","article-title":"Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs","volume":"316","author":"Katchman","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/jcpt.12759-BIB0215|jcpt12759-cit-0215","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcp.2017.02.017","article-title":"Inhibition and inactivation of human CYP2J2: implications in cardiac pathophysiology and opportunities in cancer therapy","volume":"135","author":"Karkhanis","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0216|jcpt12759-cit-0216","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1124\/jpet.110.174805","article-title":"Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth","volume":"336","author":"Chen","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/jcpt.12759-BIB0217|jcpt12759-cit-0217","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejphar.2015.07.047","article-title":"Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells","volume":"764","author":"Jeon","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/jcpt.12759-BIB0218|jcpt12759-cit-0218","first-page":"5484","article-title":"Role of cytochrome P450 2J2 on cell proliferation and resistance to an anticancer agent in hepatocellular carcinoma HepG2 cells","volume":"14","author":"Hwang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1111\/jcpt.12759-BIB0219|jcpt12759-cit-0219","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.111.043505","article-title":"Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity","volume":"40","author":"Lee","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/jcpt.12759-BIB0220|jcpt12759-cit-0220","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","article-title":"Drug repositioning and repurposing: Terminology and definitions in literature","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1111\/jcpt.12759-BIB0221|jcpt12759-cit-0221","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/10601333.2015.1064131","article-title":"Inter-ethnic differences in drug response: implications for drug development and complying with drug regulation","volume":"32","author":"Shah","year":"2015","journal-title":"Clin Res Reg Affairs"},{"key":"10.1111\/jcpt.12759-BIB0222|jcpt12759-cit-0222","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.annepidem.2014.12.007","article-title":"A pooled multisite analysis of the effects of atopic medical conditions in glioma risk in different ethnic groups","volume":"25","author":"Krishnamachari","year":"2015","journal-title":"Ann Epidemiol"},{"key":"10.1111\/jcpt.12759-BIB0223|jcpt12759-cit-0223","first-page":"2235","article-title":"Racial disparities in the molecular landscape of cancer","volume":"38","author":"Heath","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1111\/jcpt.12759-BIB0224|jcpt12759-cit-0224","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1940-6207.CAPR-15-0425","article-title":"Metformin for reducing racial\/ethnic difference in prostate cancer incidence for men with type II diabetes","volume":"9","author":"Wang","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1111\/jcpt.12759-BIB0225|jcpt12759-cit-0225","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.4065\/78.12.1479","article-title":"Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome","volume":"78","author":"Ackerman","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/jcpt.12759-BIB0226|jcpt12759-cit-0226","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cca.2005.08.007","article-title":"CYP2J2*7 single nucleotide polymorphism in a Chinese population","volume":"365","author":"Wang","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1111\/jcpt.12759-BIB0227|jcpt12759-cit-0227","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2147\/OTT.S97211","article-title":"Integrating subpathway analysis to identify candidate agents for hepatocellular carcinoma","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1111\/jcpt.12759-BIB0228|jcpt12759-cit-0228","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ijc.30526","article-title":"Effects of statins on cancer mortality and progression: a systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals","volume":"140","author":"Mei","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1111\/jcpt.12759-BIB0229|jcpt12759-cit-0229","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ejca.2008.06.025","article-title":"Statins and cancer: a systematic review and meta-analysis","volume":"44","author":"Kuoppala","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1111\/jcpt.12759-BIB0230|jcpt12759-cit-0230","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2016.69.7391","article-title":"Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR)","volume":"35","author":"Seckl","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12759-BIB0231|jcpt12759-cit-0231","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1200\/JCO.2016.72.0870","article-title":"Do statins improve survival in small-cell lung cancer?","volume":"35","author":"Popat","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12759-BIB0232|jcpt12759-cit-0232","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nrd4651","article-title":"Regulatory watch: why do oncology drugs fail to gain US regulatory approval?","volume":"14","author":"Khozin","year":"2015","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12759\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T12:38:30Z","timestamp":1751891910000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,15]]},"references-count":232,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12759","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,15]]}}}